BioSpace News Archive

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced it has entered into a placement agency agreement for the purchase and sale of 3,753,558 shares of its common stock at an offering price of $1.065 per share.

Revive Therapeutics Ltd. announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID (the “Study”).

The Colorectal Cancer Resource & Action Network (CCRAN) is proud to announce their second annual Pan-Tumor Biomarkers Conference, scheduled to take place virtually on June 20-21, 2024, from 9:30 AM to 5:00 PM ET.

Caidya, a leading provider of clinical trial solutions, is proud to announce its recent accreditation in Targeted Source Data Verification (TSDV) from Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry.

Moleculin Biotech, Inc. announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 3:00 PM ET.

Exactech, a global medical technology leader, announced first surgeries debuting the comprehensive Equinoxe® PHx™ System that received FDA 510 clearance in September 2023, marking a significant milestone in advancing shoulder trauma care.

Zumutor Biologics Inc. “Zumutor”, a Boston-based clinical stage Oncology Company developing first-in-class monoclonal antibody molecules targeting innate immunological pathways, today announced that the first patient was dosed in its Phase 1 clinical trial, with ZM008.

Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology’s (EULAR) 2024 Congress, June 12-15 in Vienna.

Springbok Analytics (www.springbokanalytics.com), a life sciences muscle analytics company, announced today its participation in a Phase 1 Clinical Trial to evaluate safe dosage for clenbuterol as a treatment for Facioscapulohumeral muscular dystrophy (FSHD).

Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced current and potential future clinical directions that can expand the use of its gene therapies to treat additional debilitating diseases.